-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, L204cljZBSLZWDBurzUxnY++7I65MbpLs/cHkhspb+YCKs5t/1D8OlJivyYaEjv4 I5uf/qgal3igAl5w4YhzSQ== 0001005477-08-002263.txt : 20080317 0001005477-08-002263.hdr.sgml : 20080317 20080317193743 ACCESSION NUMBER: 0001005477-08-002263 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080307 FILED AS OF DATE: 20080317 DATE AS OF CHANGE: 20080317 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Marucci Anthony S CENTRAL INDEX KEY: 0001429933 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 08694588 BUSINESS ADDRESS: BUSINESS PHONE: (781) 433-0771 MAIL ADDRESS: STREET 1: 66 COLD HILL DRIVE CITY: MENDAHM STATE: NJ ZIP: 07945 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 02494 BUSINESS PHONE: 7814330771 MAIL ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 021942725 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 3 1 edgar123.xml FORM 3 X0202 3 2008-03-07 0 0000744218 AVANT IMMUNOTHERAPEUTICS INC AVAN 0001429933 Marucci Anthony S 66 COLD HILL ROAD MENDHAM NJ 07945 0 1 0 0 Exec. VP & Corporate Dev. Stock Option (right to buy) 8.16 2008-03-07 2018-03-07 Common Stock 254243 D As of March 7, 2008 (the "Effective Date"), Anthony S. Marucci beneficially owns options to purchase 254,243 shares of common stock, par value $0.001 per share (the "Shares"), of AVANT Immunotherapeutics, Inc. Options to purchase 157,093 Shares are exercisable as of the Effective Date with one twenty-fourth (1/24) of the remaining options becoming exercisable each subsequent month following the Effective Date. /s/ Anthony S. Marucci 2008-03-17 -----END PRIVACY-ENHANCED MESSAGE-----